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The severe acute respiratory syndrome (SARS) epidemic was caused by the spread of a previously unrec-
ognized infectious agent, the SARS-associated coronavirus (SARS-CoV). Here we show that SARS-CoV could
inhibit both virus- and interferon (IFN)-dependent signaling, two key steps of the antiviral response. We
mapped a strong inhibitory activity to SARS-CoV nonstructural protein 1 (nsp1) and show that expression of
nsp1 significantly inhibited the activation of all three virus-dependent signaling pathways. We show that
expression of nsp1 significantly inhibited IFN-dependent signaling by decreasing the phosphorylation levels of
STAT1 while having little effect on those of STAT2, JAK1, and TYK2. We engineered an attenuated mutant of
nsp1 in SARS-CoV through reverse genetics, and the resulting mutant virus was viable and replicated as
efficiently as wild-type virus in cells with a defective IFN response. However, mutant virus replication was
strongly attenuated in cells with an intact IFN response. Thus, nsp1 is likely a virulence factor that contributes
to pathogenicity by favoring SARS-CoV replication.
Vertebrates have evolved sophisticated immunity mecha-
nisms to manage infections by pathogens. The first line of
defense is the innate immune response, which is initiated by
the rapid recognition of pathogen-associated molecular pat-
terns. In most cell types, viral RNA is sensed by RNA helicases
(18) and triggers three signaling pathways, leading to the co-
ordinated activation of the transcription factors ATF2/c-Jun,
IRF3/IRF7, and NF-B (25). In addition, double-stranded
RNA and other viral determinants are recognized by Toll-like
receptors expressed by specialized cells involved in the im-
mune response. Signaling downstream of the Toll-like recep-
tors involves various adaptor molecules and ultimately results
in the activation of the same or a closely related set of tran-
scription factors to those activated in the generic response
(reviewed in reference 18).
Virus-activated transcription factors synergize to induce the
production of a number of cytokines, including members of the
type I interferon (IFN) family (which in humans comprises 14
IFN- genes, 1 IFN- gene, and 1 IFN- gene) and the type III
IFN family (three human IFN- genes); inflammatory cyto-
kines, such as interleukin-1 (IL-1), IL-6, IL-12, tumor necrosis
factor alpha (TNF-), and TNF-; and chemokines, such as
RANTES and IL-8. Together, these cytokines signal the oc-
currence of the infection and orchestrate the innate immune
response directed against the invading virus (2, 33, 37).
Binding of type I or type III IFNs to their cognate receptors
triggers a second wave of signaling, where phosphorylation and
activation of the receptor-associated JAK1 and TYK2 kinases
result in the phosphorylation and activation of the transcrip-
tion factors STAT1 and STAT2. Activated STAT1/STAT2
forms a complex with IRF9, termed ISGF3, which activates the
transcription of a set of IFN-inducible genes by binding to their
IFN-stimulated response elements (ISREs) (1, 33, 37).
The functional consequence of these two waves of signaling
is the increased expression of IFN-inducible proteins that col-
lectively inhibit the replication of a broad spectrum of viruses
(33, 37). The importance of IFNs in vivo is underscored by
viruses having evolved a wide variety of mechanisms to circum-
vent this antiviral response and by the dramatic increase in
susceptibility to viral infection in mice where components of
the IFN system have been inactivated (10, 14, 33, 46).
A previously unknown coronavirus, severe acute respiratory
syndrome-associated coronavirus (SARS-CoV), has been iso-
lated from patients with SARS (8, 20, 29) and fulfills Koch’s
postulates as the etiological cause of the SARS epidemic (9).
SARS-CoV genome expression starts with the translation of
two large replicative polyproteins, pp1a (486 kDa) and pp1a/b
(790 kDa), which are encoded by the viral replicase gene,
which contains two open reading frames (ORFs), ORFs 1a and
1b (Fig. 1D). Expression of the ORF 1b-encoded region of
pp1a/b involves ribosomal frame shifting just upstream of the
ORF 1a translation termination codon. The pp1a and pp1a/b
polyproteins are processed by viral proteinases to yield the
functional components of the replicase complex. The replicase
mediates both replication and transcription of a set of sub-
genomic mRNAs for the expression of an additional eight
genes (26, 31).
Precious little is known, however, about the interactions
between the IFN system and SARS-CoV or other coronavi-
ruses, although putative IFN antagonists have recently been
identified through overexpression studies (17, 19). Here we
show that while SARS-CoV is sensitive to the antiviral state
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established by IFN pretreatment, two critical aspects of the
IFN response, virus- and IFN-dependent signaling, are both
inhibited in SARS-CoV-infected cells. We demonstrate that
SARS-CoV nsp1 mediates the inhibition of antiviral signaling,
at least in part, and that an attenuating mutation in nsp1
decreases the ability of SARS-CoV to replicate in cells with an
intact IFN response.
MATERIALS AND METHODS
Cell culture and viruses. VeroE6 cells are a clone of Vero cells, which are
normal epithelial cells derived from African green monkey kidneys (ATCC
CRL-1586). Calu-3 cells are tight junction-forming human epithelial lung cells
derived from the pleural effusion of a lung adenocarcinoma (ATCC HTB-55).
293T cells are a simian virus 40 large T antigen-expressing highly transfectable
derivative of 293 cells, which are derived from human embryonic kidney cells
transformed with human adenovirus type 5. These cells were grown at 37°C in
5% CO2 in Dulbecco’s modified Eagle medium containing 10% fetal bovine
serum, 50 U/ml penicillin, and 50 g/ml streptomycin. Sendai virus (SeV;
SPAFAS) was used at 25 hemagglutinating units/ml. Vesicular stomatitis virus
(VSV; Indiana strain) was grown on VeroE6 cells, and the 50% tissue culture
infective dose was determined by limiting dilution and converted to PFU using
Ka¨rber’s formula (one 50% tissue culture infective dose  0.7 PFU).
All work with live SARS-CoV was performed in a biosafety cabinet in a
biosafety level 3 (BSL3) laboratory by personnel dressed in Tyvek suits with full
hoods, face shields, and double gloves and breathing through powered air-
purifying respirators (BSL3 standard). SARS-CoV (Urbani strain) was ob-
tained from the CDC. Recombinant SARS-CoV strains, both wild type (WT)
and m1, were derived as described previously (49). Plaque-purified SARS-CoVs
were amplified on VeroE6 cells, and titers were determined by plaque assay or
limiting dilution, as indicated. Second- and third-passage SARS-CoVs were used
in all experiments, and the mutant virus was verified by sequencing.
Virus infections were performed in a small volume for 1 h, after which the
inoculum was removed and the cells were washed once before further incubation.
Because the initial infection was conducted at 37°C, the time of virus addition
was taken as time zero. All virus titrations are averages for at least three
independent experiments.
Cloning nsp cDNAs. The starting material was the Urbani strain of SARS-
CoV 3200300841 at passage 3 in TRIzol LS reagent. Each cDNA was cloned by
standard techniques (32) into a mammalian expression plasmid, pcDAF3m1, in
frame with an N-terminal triple-Flag sequence (MDYKDHDGDYKDHDIDY
KDHDE) or an N-terminal hemagglutinin tag (MAYPYDVPDYAS) and then
fully sequenced. The nsp3 construct was somewhat unstable and was propagated
FIG. 1. (A) VeroE6 cells, uninfected (U) or infected for 1 h with WT SARS-CoV (MOI, 3) or SeV, were further incubated at 37°C. Protein
extracts were harvested at the indicated times and analyzed by immunoblotting. Over the time course, the 15-kDa and 56-kDa proteins were more
induced by SeV than by SARS-CoV (7.4- and 6.2-fold, respectively) (equal amounts of protein were verified by c-Jun and IB levels [see panel
C]). (B) RNAs from cells treated as described for panel A were analyzed by Northern blotting with the indicated probes. The signals for ISG54
and ISG15 mRNAs in SARS-CoV-infected samples are not bands but a smear that corresponds to low-level degradation of the much more intense
rRNA signals that happen to also be detected by the ISG54 probe (28S rRNA) and the ISG15 probe (28S and 18S rRNAs). RNA sizes of the ISG
bands are indicated on the left, in kb. Dashes mark the positions of the nine SARS-CoV RNAs. (C) Immunoblots as described for panel A were
probed with anti-(phospho)-c-Jun or anti-(phospho)-IB antibodies. (D) Structure of SARS-CoV replicase (see the text for more details).
(E) Immunoblot analysis of extracts from 293T cells transfected with empty plasmid (	) or plasmids for the indicated Flag-nsp constructs. The


















. (F) 293T cells transfected with empty plasmid (	) or plasmids for the indicated Flag-nsp constructs, together with 	110IFNCAT,
were left uninfected (U) or infected with SeV for 18 h, and reporter activity was determined after normalization for transfection efficiency, not nsp
expression levels.
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in Escherichia coli at room temperature; each preparation was fully sequenced.
In the case of the nsp11 construct, the nsp11/nsp12 reading frames were cloned
behind the Flag sequence so that nsp11 would be produced in the absence of
frame shifting and nsp12 would be produced in its presence. In addition, an
nsp12 construct was generated to have two nucleotide substitutions (underlined)
that inactivate the “slippery” sequence required for frame shifting without alter-
ing the amino acid sequence and to have an insertion of an additional nucleotide
(underlined and in bold) to produce the correct frame for nsp12 production
(CGTTTTTAAACGGGTTT was changed to CGTTCTTGAACCGGGTTT).
For nsp1 m1 and m2, CTTCGTAAGAACGGTAATAAGGGA was mutated to
CTTagtgagAACGGTAATAAGGGA for m1 and to CTTCGTAAGAACGGTa
gtgagGGA for m2 (mutations are shown in lowercase). All mutations were made
by PCR, and the mutated region was fully sequenced.
Plasmids for H6IRF3 and c-Jun have been described previously (40, 45).
Plasmids for STAT1 (pcDAMT-STAT1) and STAT2 (pcDAH6STAT2)
contain the coding region fused to an N-terminal Myc tag (MEQKLISEEDLN)
and a hexahistidine tag, respectively. Plasmids for JAK1 (pRK-5-JAK1) and
TYK2 (pRc/CMV-TYK2-VSV) were kind gifts of J. Ihle and S. Pelligrini, re-
spectively. The plasmid for luciferase (Photinus pyralis) was generated by cloning
the coding region into pcDA. Reporters and the plasmid for Gal4-IRF7B have
been described previously (45), and Gal4-p65 and Gal4-STAT2 were similarly
constructed. All proteins were expressed from the cytomegalovirus (CMV) en-
hancer, except for the Gal4 fusions, which were expressed from the simian virus
40 enhancer.
Cell transfections and reporter assays. 293T cells (2.5 
 106) in 100-mm
dishes were transfected by calcium phosphate coprecipitation (32) with 1 ml of a
precipitate containing 5 g reporter, 0 to 15 g effector plasmid, 3 g pCMV-
lacZ, 2 g pcDA-luciferase, and pcDA to a total of 25 g for 18 h, trypsinized,
aliquoted for further treatments, and harvested 2 days after transfection (trans-
fection efficiency was routinely 95%, as determined by in situ lacZ staining).
Cell extracts were made with M-Per (Pierce). Chloramphenicol acetyltrans-
ferase (CAT), luciferase, and -galactosidase activities were determined (32);
CAT activity (computed as the percentage of conversion from unacetylated to
monoacetylated chloramphenicol from phosphorimager data [% conversion 
monoacetylated chloramphenicol/total chloramphenicol]), after normalization to
the luciferase transfection efficiency control, was expressed in arbitrary units so
that the relative strengths of reporters or activators could be estimated. Statis-
tical significance was determined using a two-tailed t test on two sets of samples,
assuming unequal variances; for the standard deviation, only the down line is
shown in Fig. 1, 3, 4, and 5.
Expression of SeV proteins was not affected by nsp1 (not shown), as previously
reported (17).
Immunoblot and Northern blot analyses. Cell extracts were analyzed by so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and im-
munoblotting as described previously (15). To ensure that equal amounts of
protein were loaded into the gel, equal numbers of cells were seeded for each
treatment and carefully harvested in the same volume of either M-Per (Pierce)
or 2
 SDS loading dye. Immunoblots with control antibodies as well as nonspe-
cific bands with some antibodies confirmed equal loading for all immunoblots
shown. We used the following commercial primary antibodies: rabbit polyclonal,
anti-SARS-CoV NP (IMG-549; Imgenex), anti-c-Jun (9162; Cell Signaling), anti-
phospho-Ser73-c-Jun (9164; Cell Signaling), anti-IB (9242; Cell Signaling),
anti-phospho-Ser32-IB (9241; Cell Signaling), anti-IRF7 (sc-9083; Santa Cruz
Biotechnology), anti-Gal4 antibody (sc-510; Santa Cruz Biotechnology), anti-
STAT1 (sc-592; Santa Cruz Biotechnology), anti-phospho-Ser727-STAT1 (9177;
Cell Signaling), anti-STAT2 (sc-22816 Santa Cruz Biotechnology), anti-phospho-
Tyr690-STAT2 (4441; Cell Signaling), anti-Jak1 (3332; Cell Signaling), anti-
phospho-Tyr1022/23-Jak1 (3331; Cell Signaling), anti-Tyk2 (ab5383; Abcam),
anti-phospho-Tyr1054/55-Tyk2 (9321; Cell Signaling), anti-VSV G (Immunol-
ogy Consultants Laboratory, Inc.), mouse monoclonal anti-phospho-Tyr701-
STAT1 (sc-8394; Santa Cruz Biotechnology), and M2 (anti-Flag; Sigma) to
detect Flag-tagged proteins. We also used rabbit polyclonal anti-UCRP (i.e.,
anti-ISG15; a kind gift of A. Haas), anti-ISG56 (a kind gift of G. Sen), anti-
SARS-CoV nsp1, anti-SARS-CoV nsp3N, anti-SARS-CoV nsp3C (VU231,
VU233, and VU235, respectively; kind gifts of M. R. Denison [30]), and the
mouse monoclonal antibody SL-12 to detect IRF3 dimerization following
deoxycholate-PAGE as described previously (48). The binding of these primary
antibodies was detected with anti-mouse or anti-rabbit immunoglobulin–horse-
radish peroxidase conjugate as the secondary antibody (Promega). The chemi-
luminescence detection system was from Perkin-Elmer Life Sciences. RNAs
were extracted with Tri-Reagent (Molecular Research), and Northern blot anal-
ysis of total RNA was performed using ISG15, ISG54, ISG56, and NP (nucleo-
tides 28,120 to 29,388) radioactive riboprobes exactly as described previously
(44).
RESULTS
Virus-dependent signaling in SARS-CoV-infected cells. Vi-
rus infection leads to the induction of a set of cellular proteins
unless the virus inhibits this antiviral response. SeV, a potent
inducer of virus-dependent signaling, induced the 15- and 56-
kDa proteins encoded by the virus- and IFN-inducible ISG15
and ISG56 genes. In contrast, induction of the ISG15 and
ISG56 products was weaker at all time points in SARS-CoV-
infected cells, where expression of SARS-CoV NP increased
over the course of infection (Fig. 1A).
The weak expression of antiviral proteins in SARS-CoV-
infected cells could be due to the inhibition of protein trans-
lation often observed during viral infections or to an inhibition
at the RNA level. The ISG15, ISG54, and ISG56 mRNAs were
undetectable in SARS-CoV-infected VeroE6 cells, while they
were expressed in response to infection by SeV (Fig. 1B)(or by
Newcastle disease virus ([44]). Expression of all SARS-CoV
RNAs could be detected using an NP probe (Fig. 1B).
The undetectable expression of antiviral mRNAs in SARS-
CoV-infected cells could be due to an inhibition of virus-
dependent signaling. The transcriptional induction of ISG
mRNAs by viruses depends on IRF3/IRF7, and activation of
IRF3 is defective in SARS-CoV-infected cells (36). Induction
of the IFN- mRNA requires ATF2/c-Jun and NF-B in ad-
dition to IRF3/IRF7. Phosphorylation of S73 in c-Jun was
readily detectable after SeV infection but was very weak in
SARS-CoV-infected cells. Similarly, phosphorylation of the
NF-B inhibitor IB on S32 was undetectable in response to
SARS-CoV but was robust in SeV-infected cells (Fig. 1C).
Thus, virus-dependent signaling appears to be weak in
VeroE6 cells infected by SARS-CoV, in marked contrast to the
response observed for SeV. We next focused on the nonstruc-
tural proteins carried by SARS-CoV as potential virulence
factors because they are expressed early, before the generation
of viral double-stranded RNA, which triggers antiviral signal-
ing.
Expression of SARS-CoV replicase proteins in human cells.
The SARS-CoV replicase polyproteins are predicted to be
processed into 16 polypeptides, nsp1 to nsp16, by a 3C-like
proteinase (3C) and a papain-like proteinase (35, 41) (Fig.
1D). 293T cells transfected with Flag-tagged nsp constructs
produced proteins of the expected sizes, with wide variations in
expression levels; e.g., nsp14 and -15 were expressed100-fold
more than nsp12 and -16 were (Fig. 1E).
Expression of Flag-nsp3, which contains the papain-like pro-
teinase activity, yielded a number of shorter polypeptides,
some of which were also observed in SARS-CoV-infected cells
(30). Expression of nsp4 is expected to produce a 56-kDa
protein, but only a 38-kDa protein has been observed in SARS-
CoV-infected cells (30). Nevertheless, we observed a protein of
56 kDa in cells transfected with Flag-nsp4, but only when the
cells were lysed in the presence of SDS, suggesting that nsp4
might be tightly associated with an insoluble cellular structure.
The nsp11 construct contained the sequence encoding nsp11
and -12, so both nsp11 and nsp12 were expected to be pro-
duced. To express nsp12 only, we introduced nucleotide sub-
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stitutions that inactivate the “slippery” sequence required for
frame shifting (41) without altering the amino acid sequence
and inserted an additional nucleotide to produce the correct
open reading frame for nsp12 production. Transfection of the
Flag-nsp11 construct resulted in the expression of nsp12
through frame shifting, but with a lower yield than that of the
Flag-nsp12 construct, as expected.
SARS-CoV nsp1 and nsp3 inhibit virus-dependent activa-
tion of the IFN- promoter. SeV is a potent IFN inducer in
human cells and has been used widely to characterize virus-
dependent signaling and the IFN- gene promoter (25). Infec-
tion by SeV of 293T cells transfected with the 	110IFNCAT
reporter led to a strong increase in CAT activity (225-fold)
(Fig. 1F). We found that coexpression of most Flag-nsps had
little effect on induction (20%). However, coexpression of
Flag-nsp1 or Flag-nsp3 each reduced induction of this pro-
moter, by factors of 6 (P  0.001) and 2.5 (P  0.001),
respectively. Expression of nsp1 also strongly affected one
transfection efficiency control used, CMV-lacZ, making it un-
suitable for experiments involving nsp1, but had no effect on
another, pcDA-luciferase, or on a CAT reporter driven by a
constitutive activator (Fig. 2). Thus, experiments could be nor-
malized for transfection efficiency by using luciferase activity,
and effects on CAT reporters reflected signal transduction/
promoter effects rather than a direct effect on expression of the
CAT enzyme.
Expression from the IFN- promoter depends on three cis-
acting elements, PRDIV, P31, and PRDII, which in virus-
infected cells are bound by the transcription factors ATF-2/c-
Jun, IRF3/IRF7, and NF-B, respectively (45). We next
investigated how nsp1 and nsp3 inhibited expression of the
IFN- promoter by determining their effects on individual
cis-acting elements and/or transcription factors.
SARS-CoV nsp1 and nsp3 inhibit activation of an NF-B-
dependent reporter. There was a strong increase in CAT ac-
tivity in cells transfected with the NF-B-dependent
PRDIIx3CAT reporter and infected with SeV (100-fold) or
treated with TNF (300-fold) (Fig. 3A). Coexpression of Flag-
nsp3 resulted in a small decrease in the response to TNF that
was not significant (P  0.07) and an 2.3-fold reduction in
response to SeV that was significant (P 0.003). Coexpression
of Flag-nsp1 significantly decreased both TNF (8.6-fold)-
and SeV (48-fold)-dependent activation of PRDIIx3CAT,
indicating that nsp1 could inhibit the NF-B pathway.
SARS-CoV nsp1 inhibits virus-dependent activation of IRF3
and IRF7. Virus-dependent phosphorylation of IRF3 and
IRF7 leads to a conformational change that converts these
latent cytoplasmic factors to active nuclear transcription fac-
tors targeting the P31 cis-acting element in the IFN- pro-
moter. Infection by SeV of cells transfected with P31x3CAT
led to a strong increase in CAT activity (40-fold) (Fig. 3B).
Coexpression of Flag-nsp3 resulted in a small, statistically in-
significant (P 0.14) increase in the response of P31x3CAT to
SeV. Coexpression of Flag-nsp1 strongly inhibited SeV-depen-
dent activation of P31x3CAT (29-fold; P  0.006) (Fig. 3B).
We next investigated the activation of IRF3 and IRF7. Cells
were transfected with a plasmid directing the expression of
IRF3 so that the signal from the fraction of cells that were
untransfected would not obscure the inhibitory effect of nsp1,
if any. Cotransfection of both IRF3 and Flag-nsp1 resulted in
a strong decrease in virus-dependent dimerization of IRF3
compared to that in cells transfected with IRF3 alone, while
nsp3 had no effect (Fig. 3C).
Activation of IRF7 independently of IRF3 was assessed us-
ing a Gal4-IRF7 fusion construct and a reporter driven by Gal4
binding sites, namely, G5E1bCAT. Infection with SeV resulted
FIG. 2. 293T cells were transfected with empty vector (Vec.) or a vector for Flag-nsp1 expression (nsp1), together with different reporters and
the CMV-lacZ and pcDA-luciferase transfection efficiency controls (used in Fig. 1, 3, 4, and 8). (A) -Galactosidase activity was assayed in a
150-l reaction mix with ortho-nitrophenyl--galactopyranoside in a 96-well plate and read on an enzyme-linked immunosorbent assay reader at
405 nm every 5 min after the start of the reaction. Values in the linear range of the assay were normalized to the average (0.634) for cells transfected
with empty vector, and nsp1 expression resulted in an average decrease to a value of 0.060, with a standard deviation of 0.040. (B) Luciferase
activity was assayed in a 60-l reaction mix by using a luciferase assay kit (Roche) and read in a Femtomaster FB12 instrument (Zylux). Values
in the linear range of the assay were normalized to the average (5,899,000) for cells transfected with empty vector, and nsp1 expression resulted
in an 11% increase, which was not statistically significant, to a value of 6,562,000 (standard deviation of 2,482,000). (C) 293T cells were transfected
with empty vector (Vec.) or a vector for Flag-nsp1 expression (nsp1), together with the G5E1bCAT reporter, which contains five copies of the
upstream activating sequence, a 17-mer binding site for Gal4, and a construct expressing the DNA-binding domain of Gal4 (amino acids 1 to 147)
fused to the full-length coding region of the 65-kDa subunit of NF-B (Gal4p65). CAT activity was assayed and normalized to luciferase activity.
The average activity of Gal4p65 activating the G5E1bCAT reporter was increased 28% when nsp1 was coexpressed, but the increase was not
statistically significant (P  0.28).
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in a robust induction of this reporter system (8.5-fold) (Fig.
3D), as previously shown (45). Coexpression of Flag-nsp1 al-
most completely blocked this activation, while the expression
level of Gal4-IRF7 itself was stimulated. In contrast, nsp1 had
little effect on the activity of Gal4-p65 (Fig. 2C) or Gal4-
STAT2 (see Fig. 5C). Thus, the virus-dependent activation of
the P31 element and of both IRF3 and IRF7 was inhibited by
coexpression of nsp1.
SARS-CoV nsp1 inhibits c-Jun expression and phosphory-
lation. The virus-dependent phosphorylation of c-Jun on S 73
by c-Jun N-terminal protein kinase can be assessed by immu-
noblotting. For cells transfected with empty vector only, phos-
phorylation of endogenous c-Jun on S73 was much stronger in
cells infected with SeV than in uninfected cells, as expected.
Cotransfection of c-Jun led to an increase in the c-Jun signal,
but while SeV infection resulted in increased phosphorylation,
a substantial basal phosphorylation was also detected. Coex-
pression of Flag-nsp3 had no discernible effects, but coexpres-
sion of Flag-nsp1 resulted in a decrease in c-Jun expression
levels and suppressed virus-dependent phosphorylation (Fig.
3E).
Physiological expression levels of nsp1 and nsp3. Flag-nsp1
levels in transiently transfected 293T cells were comparable to
the nsp1 levels observed in SARS-CoV-infected VeroE6 cells,
as determined by immunoblotting using an anti-nsp1 antibody
(the nsp1 level in 293T cells was 98% of that in VeroE6 cells at
19 h postinfection [hpi] [Fig. 3F]). In contrast, the levels of
Flag-nsp3 were substantially higher (3.4- to 16-fold) in 293T
cells than those of nsp3 in SARS-CoV-infected cells, as deter-
mined by immunoblotting using anti-nsp3 antibodies directed
against the N- and C-terminal parts of nsp3 (Fig. 3G) (nsp3 is
barely detectable in infected cells, as reported previously [30]).
Thus, expression of near physiological levels of SARS-CoV
nsp1 in isolation substantially inhibited the virus-dependent
pathways leading to activation of ATF2/c-Jun, IRF3/IRF7, and
NF-B, recapitulating the inhibition of signaling observed in
SARS-CoV-infected cells. In contrast, SARS-CoV nsp3 inhib-
ited only the NF-B pathway, inhibited it relatively weakly only
at supraphysiological levels, and was not further analyzed. Al-
though speculative, the deubiquitinating activity of nsp3 (23)
may account for its ability to inhibit the ubiquitination-depen-
dent NF-B pathway.
IFN-dependent response in SARS-CoV-infected cells. After
virus-dependent signaling and induction of IFNs, the second
step of the antiviral response is the IFN-dependent expression
of a set of cellular proteins, which leads to the establishment of
an antiviral state. VeroE6 cells were left uninfected or were
infected with SARS-CoV for 9 h, after which the cells were
FIG. 3. (A) 293T cells transfected with empty vector (Vec.) or vector for nsp1 or nsp3, together with PRDIIx3CAT, were left uninfected (U),
infected with SeV, or treated with 10 ng/ml of TNF for 18 h, and reporter activity was determined. (B) 293T cells transfected with empty vector
(Vec.) or vector for nsp1 or nsp3, together with P31x3CAT, were left uninfected (U) or infected with SeV for 18 h, and reporter activity was
determined. (C) 293T cells transfected with empty vector (Vec.) or vectors for expression of Flag-nsp1, Flag-nsp3, and/or H6IRF3 were left
uninfected (	) or infected with SeV () for 6 h, and extracts were analyzed by deoxycholate-PAGE and immunoblotting. (D) 293T cells
transfected with Gal4-IRF7B, G5E1bCAT, and empty vector (Vec.) or a vector for nsp1 were left uninfected (U) or infected with SeV for 18 h,
and reporter activity was determined. Extracts were also analyzed by immunoblotting with an anti-IRF7 antibody, which detects both Gal4-IRF7
and endogenous IRF7 (bottom). (E) 293T cells transfected with empty vector (Vec.) or vectors for nsp1, nsp3, and/or c-Jun were left uninfected
(	) or infected with SeV () for 6 h, and expression and phosphorylation of c-Jun were determined by immunoblotting. GAPDH expression did
not vary under these conditions. (F) VeroE6 cell extracts used for Fig. 1A and extracts of 293T cells transfected with empty vector (Vec.) or
Flag-nsp1 were analyzed by immunoblotting with anti-nsp1 (VU231) (30) and anti-STAT1 antibodies. (G) VeroE6 cell extracts used for Fig. 1A
and extracts of 293T cells transfected with empty vector (Vec.) or Flag-nsp3 were analyzed by immunoblotting with two anti-nsp3 antibodies
(VU235 [top] and VU233 [middle], specific for the C and N termini, respectively [30]) and anti-STAT1 antibody [bottom].
11624 WATHELET ET AL. J. VIROL.
treated with IFN and further incubated for the indicated times
(Fig. 4A). The ISG15 product was readily induced by IFN in
uninfected cells, while IFN-dependent induction in SARS-
CoV-infected cells was much reduced. Thus, induction of the
virus- and IFN-inducible 15-kDa protein is defective both in
response to virus and in response to IFN in SARS-CoV-in-
fected cells.
SARS-CoV nsp1 inhibits activation of IFN-dependent re-
porters. We used CAT reporters driven by the ISRE of the
9-27 gene or the ISG15 gene to assess the effects of nsps on
IFN-dependent signaling. Treatment of cells transfected with
the 9-27ISREx4CAT reporter with IFN- led to a strong in-
crease in CAT activity (44-fold) (Fig. 4B). Coexpression of
most Flag-nsps had little effect (16%) on induction of this
reporter. However, coexpression of Flag-nsp1 inhibited the
induction of 9-27ISREx4CAT by a factor of 16 (P  0.001).
The 9-27 gene is part of a subset of IFN-inducible genes that
respond only to IFN treatment, while there is another subset
that also respond to virus infection (44), which we also tested.
Infection with SeV or treatment with IFN- or IFN- led to
54-,450-, or15-fold activation of the ISG15 ISREx3CAT
reporter, respectively. Coexpression of nsp1 resulted in an
21-, 40-, and 29-fold inhibition of activation, respectively,
by these stimuli (Fig. 4C). We next investigated how nsp1
inhibited the IFN-dependent activation of the ISRE by deter-
mining its effect on phosphorylation events in this pathway.
SARS-CoV nsp1 inhibits STAT1 phosphorylation. When
cells are exposed to type I IFN, STAT1 becomes phosphor-
ylated on Y701 and phosphorylation on S727 is further
increased. The tyrosine phosphorylation is necessary for homo-
or heterodimerization of STAT1, while the serine phosphory-
lation increases the transcriptional activity of STAT1. Cells
were transfected with a plasmid for STAT1 and treated with
IFN- or IFN- for 0, 10, 30, or 60 min (Fig. 5A). Both IFN-
and IFN- stimulated the levels of STAT1 phosphorylated on
Y701, and coexpression of nsp1 decreased those levels while
having no effect on the levels of the STAT1 protein. Similarly,
phosphorylation of STAT1 on S727 was decreased by coex-
pression of nsp1.
SARS-CoV nsp1 only weakly inhibits STAT2 phosphoryla-
tion. When cells are exposed to type I IFN, STAT2 becomes
phosphorylated on Y690, which allows it to heterodimerize
with STAT1. IFN- stimulated the levels of STAT2 phosphor-
ylated on Y690, and nsp1 coexpression resulted in a small
decrease in the levels of phospho-STAT2 and in the levels of
the STAT2 protein (14% decrease after normalizing to the
level of STAT2) (Fig. 5B). The activation of STAT2 indepen-
dently of STAT1 was also assessed using Gal4-STAT2. Treat-
ment with IFN- resulted in a robust induction of the reporter
FIG. 4. (A) VeroE6 cells were left uninfected or were infected for
1 h with WT SARS-CoV (MOI, 5) and further incubated for 8 h.
IFN- (2,000 U/ml) was then added for 2, 4.5, and 7 h before immu-
noblot analysis. (B) 293T cells transfected with 9-27 ISREx4CAT and
empty vector (	) or Flag-nsp constructs were left untreated (Co) or
treated with 500 U/ml of IFN- for 18 h, and reporter activity was
determined. (C) 293T cells transfected with ISG15 ISREx3CAT and
empty vector (Vec.) or vector for nsp1 were left untreated (Co), in-
fected with SeV, or treated with 500 U/ml of IFN- or IFN- for 18 h,
and reporter activity was determined.
FIG. 5. (A) 293T cells transfected with empty vector (	) or vectors
for expression of nsp1 and/or STAT1 were treated with 2,000 U/ml of
IFN- or IFN- for 0, 10, 30, and 60 min, and extracts were analyzed
by immunoblotting. (B) 293T cells transfected with empty vector (	)
or vectors for nsp1 and/or STAT2 were treated with 2,000 U/ml of
IFN- for 0, 10, 30, and 60 min, and extracts were analyzed by immu-
noblotting. (C) 293T cells transfected with Gal4-STAT2, G5E1bCAT,
and empty vector (Vec.) or a vector for nsp1 were left untreated (Co)
or treated with 500 U/ml of IFN- or IFN- for 18 h, and reporter
activity was determined. Extracts were also analyzed by immunoblot-
ting with an anti-STAT2 antibody, which detects the Gal4-STAT2
fusion and endogenous STAT2. Lanes 1 to 3, cells transfected with
empty vector; lanes 4 to 6, cells transfected with Gal4-STAT2; lanes 7
to 9, cells transfected with Gal4-STAT2 and nsp1. Cells were left
untreated (lanes 1, 4, and 7) or were treated for 18 h with 500 U/ml of
IFN- (lanes 2, 5, and 8) or IFN- (lanes 3, 6, and 9).
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driven by Gal4 binding sites, i.e., G5E1bCAT (12-fold) (Fig.
5C). Treatment with IFN- led to a modest induction (1.4-fold;
P 0.006). Expression of nsp1 led to a small, insignificant (P
0.14) increase in IFN--dependent activation of Gal4-STAT2
and had no effect on IFN--dependent activation. The expres-
sion levels of the Gal4-STAT2 fusion protein were stimulated
by coexpression of nsp1, like the case for Gal4-IRF7. Thus,
phosphorylation and activation of STAT2 were minimally af-
fected by nsp1 expression.
SARS-CoV nsp1 does not inhibit JAK phosphorylation.
Phosphorylation of STAT1 and STAT2 upon type I IFN treat-
ment is effected by two JAK kinases associated with the type I
IFN receptor, JAK1 and TYK2. Binding of IFN to its receptor
leads to the phosphorylation of JAK1 on Y1022 and Y1023
and of TYK2 on Y1054 and Y1055, which can be detected with
specific antibodies. Transient expression of JAK1 had a non-
linear dose response and was strongly inhibited by nsp1 (Fig.
6A). To assess JAK1 phosphorylation, different levels of JAK1
were transfected in the presence or absence of nsp1 and dif-
ferent amounts of extracts were used for immunoblot analysis
so that the total amounts of JAK1 were comparable (Fig. 6B).
IFN-dependent phosphorylation of both JAK1 and TYK2 was
detected, and nsp1 had little or no effect on phosphorylation of
either kinase when the total amount of each kinase was taken
into account. Thus, it appears that expression of nsp1 resulted
in substantially decreased levels of STAT1 phosphorylation on
both Y701 and S727 and in a dramatic inhibition of JAK1
expression while having little effect on the phosphorylation
levels of STAT2, JAK1, and TYK2.
Pleiotropic activities of nsp1. Besides inhibiting antiviral
signaling, we found that nsp1 displayed multiple activities. We
observed the following differences between 293T cells trans-
fected with Flag-nsp1 and cells transfected with empty vector
or other Flag-nsp constructs: (i) a significant decrease was
observed in the total protein concentration of cell extracts
(with, on average, an 40% reduction 2 days after transfec-
tion); (ii) reduced metabolism was seen (as indicated by the pH
of the culture medium); and (iii) when cells were cotransfected
with a vector for expression of enhanced green fluorescent
protein (EGFP), the number of fluorescent cells did not in-
crease from the first day after transfection to the next only in
the presence of Flag-nsp1 (not shown). To quantitatively doc-
ument any effect of nsp1 on cell proliferation, transfected cells
were fixed, stained with propidium iodide (PI) in the presence
of RNase A, and analyzed using flow cytometry exactly as
described previously (6). This method allows the determina-
tion of DNA content and provides an estimate of the distribu-
tion of a cell population in the various phases of the cell cycle.
We found that with EGFP-positive cells, more cells were in the
G0/G1 phase of the cycle at the expense of the G2/M phase
when nsp1 was present (Fig. 7). Gating on EGFP-negative cells
(i.e., untransfected cells) showed the same cell cycle distribu-
tion as gating on EGFP-positive cells transfected with vector
alone, as expected.
This inhibition of cell cycling did not lead to programmed
cell death, as determined with unfixed cells stained with an-
nexin V-allophycocyanin and PI, exactly as described previ-
ously (43). Annexin V staining detects the phospholipid phos-
phatidylserine, which is translocated from the inner leaflet of
the plasma membrane to the outer leaflet in the early phase of
apoptosis, and PI staining detects a compromised cellular
membrane. These markers allow the identification of healthy,
early apoptotic, late apoptotic/necrotic, and dead cells. We
found that nsp1 expression decreased the percentage of apop-
totic cells compared to that for cells transfected with empty
vector (Table 1).
Moreover, expression of nsp1 led to decreased expression of
some proteins (-galactosidase, c-Jun, and JAK1) and in-
creased expression of others (Gal4-IRF7 and Gal4-STAT2),
FIG. 6. (A) 293T cells were transfected with the indicated amounts
of a JAK1 expression vector and with empty vector (	) or a vector for
nsp1 (), and the levels of JAK1 were determined by immunoblotting.
(B) 293T cells transfected with empty vector (	) or vector for JAK1 or
TYK2, with or without nsp1, were treated with 2,000 U/ml of IFN- for
0, 10, 30, and 60 min, and extracts were analyzed by immunoblotting.
To compensate for the effect of nsp1 on JAK1 levels, 10 l of extracts
transfected with 7 g of JAK1 and 30 l of extracts cotransfected with
15 g of JAK1 and 15 g of nsp1 were loaded in the gel.
FIG. 7. 293T cells transfected with empty vector (Vec.) or a vector
for nsp1, together with pcDA-eGFP, for 48 h were fixed, stained with
PI in the presence of RNase A, and analyzed using flow cytometry to
determine DNA content and the distribution of the cell population in
the various phases of the cell cycle.
















Empty vector 1.28 1.61 91.12 5.99
nsp1 vector 0.03 0.12 97.44 2.41
a 293T cells were transfected with empty vector or a vector for nsp1, together
with pcDA-eGFP, for 48 h, and unfixed cells were stained with annexin V-
allophycocyanin and PI exactly as described previously (43).
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while most (e.g., luciferase, CAT, IRF3, STAT1, and TYK2)
were not affected (Fig. 2, 3, 5, and 6).
Activity of SARS-CoV nsp1 mutants. To determine if nsp1
antagonist functions can be ablated, we introduced point mu-
tations targeting amino acids predicted to be at the surface of
the protein into nsp1 and, in this study, further characterized
two among the mutants that had reduced activity, namely, m1
and m2. In nsp1 m1, R124 and K125 were replaced with S124
and E125, while in nsp1 m2, N128 and K129 were converted to
S128 and E129. Cotransfection of mutant or WT nsp1 with a
virus- or IFN-inducible reporter showed that the inhibitory
effects of mutant nsp1 on the responses were much reduced
compared to those of the WT (Fig. 8A) under conditions
where the expression levels of the mutant nsp1s were close to
those of WT nsp1 (bottom panel). In most experiments, how-
ever, nsp1 m1 and m2 were expressed at lower levels than the
WT (2- to 3-fold lower) and had few remaining inhibitory
effects on the response to virus (19 and 27% inhibition, respec-
tively) or IFN (14 and 19% inhibition, respectively) at those
levels. These mutations also had much less inhibitory activity
towards CMV-lacZ expression (WT, m1, and m2 had 83, 24,
and 17% inhibition, respectively).
The identification of inhibitory mutations in nsp1 makes it
possible to test the hypothesis that nsp1 is a virulence factor
that allows SARS-CoV to evade the antiviral response. The
nsp1 m1 mutation was introduced in the context of SARS-CoV
by reverse genetics, and the growth curves for two SARS-CoV
m1 plaques, p1 and p3, in VeroE6 cells were compared to
those for the Urbani strain of SARS-CoV and recombinant
WT SARS-CoV (Fig. 8B). The growth of SARS-CoV m1 p1
and p3 appeared to be unaffected compared to that of the WT
strains, and sequencing confirmed mutation of only R124S and
K125E in the recombinant viruses (data not shown). Expres-
sion of NP at 11 and 19 hpi was indistinguishable between the
WT and m1 viruses, while the levels of nsp1 appeared to be
decreased in the m1 viruses at the earlier time point (Fig. 8C).
Virus- and IFN-dependent responses in SARS-CoV m1-in-
fected cells. The functional consequences of the nsp1 muta-
tions introduced into SARS-CoV were investigated in VeroE6
cells and Calu-3 cells, which are lung epithelial cells with an
intact IFN response (see below).
In VeroE6 cells, induction of ISG15 was much stronger with
SARS-CoV m1 than with the WT at 12 and 18 hpi, while NP
expression was not affected and expression of nsp1 was lower
(Fig. 9A). In Calu-3 cells, induction of the ISG15 product was
also stronger with SARS-CoV m1 than with the WT (3.9-
FIG. 8. (A) 293T cells were transfected with empty vector (Vec.) or vectors for WT or mutant Flag-nsp1 and reporters, as indicated. Cells
transfected with 	110IFNCAT were left uninfected (U) or infected with SeV, and cells transfected with 9-27 ISREx4CAT were left untreated
(Co) or treated with 500 U/ml of IFN- for 18 h before reporter activity was determined. These extracts were also analyzed for nsp1 levels by
immunoblotting (bottom). (B) Ninety percent confluent VeroE6 cells were infected with the indicated viruses at an MOI of 0.5. Supernatants
were harvested at the indicated times postinfection, and their titers were determined by plaque assay. (C) VeroE6 cells were left uninfected (U) or
were infected at an MOI of 3, and extracts were harvested at the indicated times for immunoblot analysis.
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versus 2.8-fold), but the extent of the induction was partially
masked by the rather high basal levels of the 15-kDa protein in
these cells (Fig. 9D).
VeroE6 cells were also infected at three multiplicities of
infection (MOI), namely, 0.01, 0.1, and 1, for 24 h (Fig. 9B).
At all doses, ISG15 was substantially more induced by SARS-
CoV m1 than by the WT, but there were no differences in NP
and nsp1 levels of expression, indicating that at these MOI,
production of these viral proteins had reached steady-state
levels by 24 hpi. The same experiment with Calu-3 cells again
showed stronger induction of the ISG15 product by SARS-
CoV m1 than that by the WT, with lower NP and nsp1 levels.
The levels of STAT1 phosphorylation, which would reflect
ongoing action by SARS-CoV-induced IFN, were also as-
sessed. Phosphorylation of STAT1 on Y701 was consistently
higher and was sustained longer in cells infected by SARS-CoV
m1 than in those infected by the WT (Fig. 9A) (the sum of
Y701 phosphorylation normalized to STAT1 levels at 6, 12,
and 18 hpi was 2.1-fold higher in response to the mutant
virus for both cell lines). Thus, the decreased inhibitory activity
of nsp1 m1 tested in isolation resulted in increased signaling
and increased induction of a virus- and IFN-inducible gene
product in the context of the virus.
The response to exogenous IFN in VeroE6 cells showed very
little induction of ISG15 by IFN in WT SARS-CoV-infected
cells over the levels achieved with the WT virus alone (Fig.
9C). In SARS-CoV m1-infected VeroE6 cells, IFN treatment
led to an increase in the levels of the 15-kDa protein reached
by infection alone, but without reaching the levels achieved by
IFN treatment in uninfected cells. In Calu-3 cells infected by
WT SARS-CoV, there was a small increase in ISG15 levels in
response to IFN treatment (36%  12% of the increase ob-
served in uninfected cells), and this increase was more sub-
stantial in SARS-CoV m1-infected cells (67%  2%) (Fig.
9C). Thus, the response to exogenous IFN was stronger in
SARS-CoV m1-infected cells than in cells infected by the WT
for both cell lines, but it remained partially inhibited. Expres-
sion of ISG15 from the CMV promoter was little affected by
nsp1, suggesting that the data in Fig. 9A to D reflect effects on
signaling rather than on ISG15 mRNA expression (Fig. 9E).
Antiviral activity against VSV. Before addressing the effec-
tiveness of the antiviral state against SARS-CoVs, we chal-
lenged IFN-treated cells with VSV, which is very sensitive to
IFN. At 18 hpi, supernatants were titrated (Fig. 10A) and cell
extracts were analyzed by immunoblotting (Fig. 10B). While
VeroE6 cells readily responded to IFN- by inducing ISG15,
the antiviral state against VSV was weak, with a substantial
decrease in VSV G protein expression and VSV titers ob-
served only with high doses of IFN (1,000 U/ml and higher)
and with a net decrease in virus yield of only 300-fold (from
7 
 107 to 2.2 
 105 PFU/ml). In contrast, strong reductions in
titers and levels of VSV G were observed in Calu-3 cells with
a much lower IFN dose (30 U/ml), and the virus yield de-
creased by a factor of 20,000 (from 1 
 107 to 4.8 
 102
PFU/ml). Thus, a strong antiviral state can be established in
Calu-3 cells, while the antiviral state in VeroE6 cells is weak
and requires high doses of IFN.
Antiviral activity against SARS-CoVs. In VeroE6 cells, IFN
pretreatment had no significant effect on replication of SARS-
CoVs from 3 to 300 U/ml, and higher doses of IFN had a
relatively modest effect (Fig. 10C and E), reducing virus rep-
lication by a factor of 15 (from 1.6 
 106 to 1.1 
 105
PFU/ml). The difference in replication between the WT and
mutant SARS-CoVs was very small (average, 1.4-fold) and
was not statistically significant. In Calu-3 cells, IFN pretreat-
ment reduced SARS-CoV replication in a dose-dependent
FIG. 9. (A) Immunoblot analysis of extracts from confluent VeroE6 or Calu-3 cells that were left uninfected (U) or infected with WT or m1p1
SARS-CoV (MOI, 1) for the indicated times (h) or with SeV for 12 h [or 6 h in the case of anti-(phospho)-STAT1]. (B) Immunoblot analysis
of extracts from confluent VeroE6 or Calu-3 cells that were left uninfected (U) or infected with WT or m1p1 SARS-CoV at the indicated MOIs
(0.01, 0.1, or 1) for 24 h or with SeV for 18 h [or 12 h in the case of anti-(phospho)-STAT1]. (C) Confluent VeroE6 or Calu-3 cells were left
uninfected (U) or infected with WT or m1p1 SARS-CoV (MOI, 0.1 for VeroE6 cells and 1 for Calu-3 cells) for 24 h and treated with 500 U/ml
IFN- from 16 to 24 hpi (the last 8 h). Cell extracts were analyzed by immunoblotting. (D) Immunoblot analysis of extracts from the VeroE6 and
Calu-3 cells used for panel C that were run side by side to directly compare the relative levels of expression of ISG15 is uninfected cells (U), cells
infected with SARS-CoV ml (ml), and cells treated with IFN. (E) Immunoblot analysis of ISG15 ectopically expressed in 293T cells by transfection
of a construct driven by the CMV promoter, pcDA-hISG15, in the presence or absence of constructs for expression of nspl or ml, as indicated.
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manner (Fig. 10D and E), decreasing it as much as 560-fold
for the WT and 360-fold for m1. The average difference in
replication titers between the WT and mutant viruses was
small (2.4-fold) and presumably reflects the higher induction
of IFN and other antiviral proteins by the mutant virus. Thus,
IFN established an effective antiviral state against both viruses
in response to IFN in Calu-3 cells but not in VeroE6 cells.
Attenuation of SARS-CoV m1 in cells with an intact IFN
response. We next investigated the functional consequences of
increased signaling on viral replication. Under conditions that
minimize the impact of the IFN response (short replication
time [12 h] and an MOI of 1), there was no significant effect
of the nsp1 mutation on SARS-CoV replication in cells with a
defective IFN response (Fig. 10F, VeroE6).
However, under conditions that mimic a natural infection,
i.e., a low MOI, longer incubation times, and an intact IFN
response, there was a drastic difference in replication between
the nsp1 mutant SARS-CoV and the WT (Fig. 10G, Calu-3).
Thus, SARS-CoV m1 titers were lower than WT titers by
factors of 8, 29, and 390 at 24, 36, and 48 hpi, respectively, in
Calu-3 cells. In contrast, in VeroE6 cells under the same con-
ditions, the SARS-CoV m1 titers were lower than WT titers by
factors of only 2.3, 4.6, and 2.7 at 24, 36, and 48 hpi, respec-
tively (Fig. 10G, VeroE6).
WT SARS-CoV’s ability to weakly activate antiviral signal-
ing had an impact on its replication in cells with an intact IFN
response. This was manifested by reduced titers in Calu-3 cells
compared to those in VeroE6 cells when cells were infected at
FIG. 10. (A and B) Confluent VeroE6 and Calu-3 cells were left untreated (lanes 0 and 1) or pretreated with increasing concentrations of
IFN- (lanes 2 to 9, 3, 10, 30, 100, 300, 1,000, 3,000, and 10,000 U/ml) for 24 h. Cells were left uninfected (U) or were infected with VSV for 1 h
(MOI, 1), after which all cells were washed and further incubated for 17 h, when supernatants were titrated by limiting dilution (A) and cell
extracts were analyzed by immunoblotting (B). (C to E) Confluent VeroE6 and Calu-3 cells were pretreated with increasing concentrations of
IFN- as described above, infected with WT SARS-CoV (W) or m1 (m) for 1 h (MOI, 1) or left uninfected (U), washed, and further incubated
for 17 h, when supernatants were titrated by limiting dilution (C and D) and cell extracts were analyzed by immunoblotting (E). (F) Confluent
VeroE6 and Calu-3 cells were infected with WT SARS-CoV and m1 (MOI, 1) for 12 h, and titers were determined by limiting dilution.
(G) Confluent VeroE6 and Calu-3 cells were infected with WT SARS-CoV and m1 at a low MOI of 4 
 10	5, and supernatants were harvested
at the indicated times (hpi) and titrated by limiting dilution. Each data point represents the average titer of 9 samples for VeroE6 cells with titers
of at least 7 
 105 PFU/ml at 48 hpi or the average titer of 12 samples for Calu-3 cells (for Calu-3 cells, two WT SARS-CoV samples and six
SARS-CoV m1 samples had undetectable levels of virus, i.e., 4.4 PFU/ml).
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a low MOI. (as much as 600-fold at 36 hpi for WT SARS-
CoV) (Fig. 10G). Thus, the sensitivity of SARS-CoV to the
antiviral effects of IFN makes inhibition of antiviral signaling
necessary for efficient replication, and this inhibition of signal-
ing is mediated, at least in part, by nsp1.
DISCUSSION
SARS-CoV is sensitive to the antiviral state induced by type
I IFNs, both in vitro (5, 38, 51; this study) and in vivo (13),
prompting us to test the hypothesis that SARS-CoV inhibits
IFN production and/or IFN-dependent signaling. Here we
show that SARS-CoV can inhibit both virus- and IFN-depen-
dent signaling, two key steps of the antiviral response. Using a
transfection-based screen, which might not be as sensitive as
screens based on heterologous viral expression (19) because
several proteins were expressed at low levels (Fig. 1E), we
identified nsp1 and nsp3 as potential IFN antagonists. How-
ever, only nsp1 inhibited antiviral signaling when expressed in
isolation at physiological levels. We found that nsp1 by itself
recapitulated the inhibition of signaling observed in infected
cells and that the signaling inhibition in SARS-CoV-infected
cells was mediated, at least in part, through nsp1.
Virus-dependent signaling. IFN- induction has been shown
to be defective in SARS-CoV-infected cells (4, 36, 52). Here
we show that all three virus-dependent pathways were only
weakly activated by SARS-CoV compared to their activation
by SeV. SARS-CoV-dependent phosphorylation of c-Jun and
IB was very weak, as was induction of ISG15 (Fig. 1). ISG15
induction depends on IRF3/IRF7 activation, and dimerization
of IRF3 was not detected in SARS-CoV-infected cells (36).
Expression of nsp1 in isolation also inhibited the three virus-
dependent pathways, namely, SeV-dependent activation of (i)
an NF-B-dependent reporter, (ii) IRF3 and IRF7, and (iii)
c-Jun (Fig. 3). Introduction of a mutation that decreased the
inhibitory activity of nsp1 in the context of SARS-CoV resulted
in an increased production and action of IFN, as determined
by STAT1 phosphorylation, and an enhanced expression of
ISG15 compared to those induced by the WT virus (Fig. 9).
Thus, SARS-CoV inhibits all virus-dependent pathways, at
least in part, through expression of nsp1.
IFN-dependent signaling. Induction of ISG15 by IFN was
weak in SARS-CoV-infected cells compared to that in unin-
fected cells, and expression of WT but not mutant nsp1 sub-
stantially inhibited IFN-dependent reporters. nsp1 specifically
decreased the phosphorylation levels of STAT1 while having
little effect on STAT2, JAK1, and TYK2 phosphorylation (Fig.
5 and 6). Accordingly, induction of ISG15 by IFN in cells
infected with SARS-CoV m1 was stronger than that in cells
infected with WT virus (Fig. 9). Thus, SARS-CoV inhibits
IFN-dependent signaling, at least in part, through expression
of nsp1 and specific inhibition of STAT1 phosphorylation.
Inhibition of cell cycling. We found that nsp1 inhibited cel-
lular proliferation and progression through the cell cycle with-
out affecting cell viability (Fig. 7; Table 1). The ortholog of
nsp1 in mouse hepatitis coronavirus, p28, has also been shown
to arrest the cell cycle in the G0/G1 phase (3), and we have
observed that p28 inhibits antiviral signaling, too, although less
efficiently than SARS-CoV nsp1 (M. G. Wathelet, unpublished
data). Thus, nsp1 and other SARS-CoV proteins, e.g., NP and
ORF7a (39, 50), could contribute to the inhibition of cell
proliferation observed in SARS-CoV-infected cells (27). This
inhibition of cell cycle progression might impact the recovery
from lung injury, as alveolar repair depends on type II alveolar
epithelial cell proliferation to replace, after differentiation, the
fragile type I alveolar epithelial cells (12).
SARS-CoV nsp1 mechanism of action. Expression by tran-
sient transfection of several genes, i.e., those encoding LacZ,
c-Jun, and JAK1, under the control of the CMV enhancer was
inhibited by nsp1. However, the expression of other genes
under the control of that enhancer was not affected by nsp1
(e.g., the luciferase, IRF3, STAT1, and TYK2 genes), suggest-
ing that nsp1 acted at the posttranscriptional level (Fig. 2, 3, 5,
and 6). Recently, SARS-CoV nsp1 was shown to suppress lacZ
and luciferase expression through mRNA degradation (17).
Although lacZ mRNA degradation caused by nsp1 expression
is consistent with our data, we did not observe a decrease in
luciferase activity in cells expressing nsp1 (Fig. 2B). It is pos-
sible that sequences flanking the luciferase coding region are
the targets of nsp1 and that they differ in the two studies. Our
observation that the expression of a number of proteins was
either not affected or stimulated by nsp1 indicates that nsp1
does not promote a general gene expression shutoff through
host mRNA degradation. In addition, several chemokine
mRNAs were recently reported to be induced by expression of
nsp1 alone, possibly through nuclear translocation of p65 (21).
This contrasts with our observations, with different cell lines,
that phosphorylation of IB was blocked in SARS-CoV-in-
fected cells and that nsp1 inhibited the activation of an NF-
B-dependent reporter by either SeV or TNF (Fig. 1C and
3A); further studies are needed to resolve this issue.
Kamitani and colleagues also reported that IRF3 dimeriza-
tion is not affected by nsp1 expression, in contrast to our
observations (Fig. 3C) and to the report that IRF3 fails to
dimerize in SARS-CoV-infected cells (36). The inhibition of
IRF3 dimerization by nsp1 is consistent with the inhibition of
the P31x3CAT reporter and the inhibition of Gal4-IRF7 (Fig.
2). A difference between the experimental procedures might
account for the discrepancy: we cotransfected 293T cells with a
plasmid directing the expression of IRF3 so that the signal
from the fraction of cells that were untransfected or ineffi-
ciently transfected would not obscure the inhibitory effect of
nsp1, while Kamitani and colleagues did not (17).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and
-actin mRNAs were identified as cellular mRNAs whose lev-
els are decreased in cells transfected by nsp1 or infected by
SARS-CoV (17). We observed a time- and dose-dependent
decrease in the levels of both GAPDH and -actin proteins in
VeroE6 cells infected by SARS-CoV, but not in Calu-3 cells
(Fig. 4A and 9). As noted above, nsp1 m1 is attenuated not
only for inhibition of signaling but also for inhibition of lacZ
expression. Nevertheless, there was no obvious difference be-
tween WT and mutant viruses for expression of these two
cellular proteins (Fig. 9A and B). While the biological signif-
icance of lower expression of GAPDH and -actin in response
to SARS-CoV replication is unclear, we have identified JAK1
as a target of nsp1, and decreased expression of JAK1 could
account for the inhibition of STAT1 phosphorylation (Fig. 5
and 6).
Several mechanisms, which are not necessarily mutually ex-
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clusive, could account for nsp1’s multiple activities. (i) nsp1
could destabilize a specific set of mRNAs directly or by in-
creasing the activity or modifying the specificity of an endog-
enous nuclease. This mechanism might account not only for
the reduced expression of a number of proteins but also for the
observed defects in signaling if some of the mRNAs encoding
key pathway components, such as JAK1, happen to be desta-
bilized by nsp1. (ii) nsp1 could target the activity of one or a
few proteins involved in signaling. This mechanism might ac-
count not only for the signaling inhibition but also for the
destabilization of a specific set of mRNAs because mRNA
stability can be controlled by signaling events. (iii) nsp1 could
have independent activities, with one affecting mRNA stability
and the other affecting signaling. Clearly, further studies are
required to determine exactly how nsp1 exerts its effects.
SARS-CoV replication in IFN-sensitive cells. The SARS-
CoV receptor is expressed on ciliated tracheobronchial epithe-
lial cells, which can be infected productively by SARS-CoV in
vivo (Wathelet, unpublished data), in vitro, and ex vivo, with
entry and release through the apical domain and with cyto-
pathic effects (34). Calu-3 cells are human lung epithelial cells
from a bronchial adenocarcinoma that form a monolayer with
tight junctions. They can be infected by SARS-CoV with cyto-
pathic effects, with virus entry and release primarily through
the apical domain (42). These properties of Calu-3 cells, their
ease of propagation, and their sensitivity to IFN (this study)
make them a very useful and relevant model for studying
SARS-CoV in vitro.
Even though WT SARS-CoV activated antiviral signaling
only very weakly (Fig. 1 and 9), this ability had an impact on its
replication in cells with an intact IFN response. Thus, when
cells were infected under conditions that maximized the IFN
response, WT SARS-CoV replicated much more slowly in
Calu-3 cells than in VeroE6 cells (8.5 
 102 PFU/ml in Calu3
cells versus 5.3 
 105 PFU/ml in VeroE6 cells, a 2.8-log dif-
ference, at 36 hpi) (Fig. 10G). This slower replication in Calu-3
cells is not due to an intrinsically lower rate of replication of
SARS-CoV in these cells. When cells were infected under
conditions that minimized the IFN response, SARS-CoV pro-
duction in Calu-3 cells (1.2
 106 PFU/ml) compared favorably
with the yield obtained from VeroE6 cells (2.5 
 105 PFU/ml)
(Fig. 10F). Therefore, the slower replication at a low MOI can
only be explained by an extrinsic factor released by the infected
cells, i.e., by secreted IFN, which has had the time to act on
uninfected cells and protect them from subsequent infection by
the virus.
Under conditions that mimic natural infection, there was a
drastic difference in the growth kinetics of SARS-CoV m1
compared to that of the WT in Calu-3 cells (2.6 log at 48 hpi)
(Fig. 10G). This difference is comparable to that observed for
influenza virus when NS1 is mutated (1.4 log at 48 hpi) (7) or
deleted (2.6 log at 48 hpi) (11). The difference in replication
between WT and mutant SARS-CoV is fully consistent with
the increased virus- and IFN-dependent signaling observed in
cells infected by the mutant virus (Fig. 9) and with the IFN
dose dependence in establishing an antiviral state in Calu-3
cells (Fig. 10D and E). In contrast, the difference in replication
of the two strains was minimal in VeroE6 cells under these
conditions (Fig. 10G). VeroE6 cells appear to be largely resis-
tant to the establishment of an antiviral state in response to
IFN, and this is not due to a defect in signaling, as the induc-
tion of ISG15 was robust (Fig. 10A to E). Rather, expression of
protein kinase R, a key antiviral enzyme (33, 37), is attenuated
in VeroE6 cells, in part due to aberrant splicing (28). The
difference between the two strains was also minimal in Calu-3
cells infected at a high MOI after 12 h (Fig. 10F), because
under these conditions there is not enough time for the full
establishment of an antiviral state.
Another manifestation of this phenomenon was observed
when cells were infected at different MOIs (Fig. 9B). In
VeroE6 cells, replication was unimpeded by IFN, and by 24
hpi, the maximum steady-state levels of NP and nsp1 had been
reached for all MOIs tested. In contrast, replication at lower
multiplicities was slowed in Calu-3 cells, and the effect was
more marked with the mutant virus, implicating IFN produc-
tion and action in this effect.
While SARS-CoV is not as sensitive to the antiviral state as
VSV is (Fig. 10), its sensitivity to the antiviral effects of IFN
makes inhibition of antiviral signaling necessary for efficient
replication. When a mutation in nsp1 that decreased its ability
to inhibit signaling was engineered into SARS-CoV, the rep-
lication of the resulting virus was attenuated under conditions
where the IFN response can take place, as hypothesized. The
difference between replication of WT SARS-CoV in VeroE6
cells and that of SARS-CoV m1 in Calu-3 cells reflects the
total impact of the IFN response, with an 20,000-fold de-
crease in titer at 36 and 48 hpi (Fig. 10G).
We concluded that nsp1 is a virulence factor that allows
SARS-CoV to evade the IFN response in cell culture by in-
hibiting, directly and/or indirectly, the expression of virus- and
IFN-inducible proteins involved in the antiviral response to
SARS-CoV, based on the following four key findings: (i) virus-
and IFN-dependent signaling is inhibited in SARS-CoV-in-
fected cells, (ii) nsp1 expressed in isolation can inhibit virus-
and IFN-dependent signaling, (iii) virus- and IFN-dependent
signaling is higher in cells infected with mutant SARS-CoV
than in those infected with WT virus, and (iv) SARS-CoV with
an attenuating mutation in nsp1 replicates normally in cells
with a defective IFN response and replicates much less effec-
tively than WT virus in cells with an intact IFN response, but
only under conditions that allow the IFN response time to
develop.
Viruses have evolved a variety of mechanisms to evade the
IFN response. Some viruses directly antagonize specific com-
ponents of virus-dependent signaling, specific components of
IFN-dependent signaling, or specific components of IFN ef-
fector pathways. In addition, some viruses indirectly antago-
nize the antiviral response by inhibiting general mechanisms of
host cell gene expression. While such inhibition is nonspecific,
it has been demonstrated that it is the indirect inhibition of the
IFN response that is biologically significant. Moreover, some
viruses evade the IFN response by a combination of direct and
indirect mechanisms (reviewed in references 10, 14, 22, 33, 46,
and 47 and in references therein). Here we show that SARS-
CoV could evade the IFN response directly by inhibiting an-
tiviral signaling and/or indirectly by affecting mRNA stability.
Another recent study identified proteins expressed from
SARS-CoV subgenomic mRNAs as IFN antagonists when
overexpressed in heterologous systems (19), but the effect of
inactivating these proteins on SARS-CoV replication in IFN-
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sensitive cells remains to be determined. The presence of mul-
tiple IFN antagonists in the SARS-CoV genome is intriguing
but not unique (10, 14, 22, 33, 46, 47). It underscores the
importance of evading the IFN response, and multiple antag-
onists may favor replication of this virus in different cell types
and different species.
Pathophysiological relevance of our observations. The im-
portance of IFN in controlling the replication of SARS-CoV is
underscored by the worsening of symptoms in mice with
STAT1 inactivation (16). The observation that SARS patients
appeared to benefit from IFN treatment (24) suggests that the
levels of IFN naturally produced in vivo are suboptimal, which
is consistent with our observation that SARS-CoV and nsp1
inhibited IFN production. Prophylactic treatment of macaques
with IFN reduces viral replication and pulmonary damage,
while postexposure treatment yields intermediary results (13).
Treatment of SARS patients with IFN would be expected to
have little effect on replication in infected cells because of
inhibition of IFN-dependent signaling but to effectively protect
other cells from subsequent infection. Thus, our findings
strengthen the rationale for using IFN to treat SARS patients.
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